An open-label analyze was carried out in 2016 in britain to analyze the feasibility, safety and efficacy of psilocybin in managing patients with unipolar treatment-resistant depression with promising results; although the research was modest and involved only twelve sufferers, seven of All those clients met formal conditions for remission a single